Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib

Giovannetti E, Zucali PA, Tibaldi C, Leon GL, Cortesi F, D’Incecco A, Falcone A, Santoro A, Smit EF, Burgers S, Danesi R, Giaccone G, Peters GJ

Presentation on “SNPs in Akt” at EORTC-NCI-ASCO (ENASCO) 2009

EORTC-NCI-ASCO Meeting
Brussels, 16th October 2009

Pdf: ENASCO2009